Regeneron

April 23 (UPI) — On Thursday, President Donald Trump announced a new drug price deal with Regeneron, the latest to agree to the “most favored nation” price policy the White House has pushed since last year.

The price deals involve voluntary price cuts by manufacturers for drugs sold to the public and the government through the TrumpRx website. In return, the manufacturers get breaks on Trump’s tariffs and other perks.

In addition, Regeneron also announced Thursday that the Federal Food and Drug Administration has approved Otarmeni, a gene therapy for genetic hearing loss. The company said the therapy would be available free in the United States.

The company is the last of the 17 the administration sought for the price policy, but officials said that more will follow. Smaller companies may also look to make deals.

“It’s not the finish line,” said Chris Klomp of the Department of Health and Human Services, who was chief negotiator on the deals, the Washington Post reported.

For the most part, the discounts do not affect people with private insurance or those on Medicaid, Axios reported. They do affect Medicaid drug prices and those buying through the TrumpRx website.

Trump called the program “the biggest price reduction in drugs in history.”

However, some have said the prices are higher through TrumpRx than through other sources, the Washington Post reported. Some lawmakers also are calling for the confidential terms of the agreements to be released, a subject that came up in hearings this week with Health and Human Service Secretary Robert F. Kennedy Jr, who has not committed to such a release.